Clinical trials: Prednisone, completed
Eosinophilia, Hypereosinophilic Syndrome
Steroid Treatment for Hypereosinophilic Syndrome
Background: Hypereosinophilic syndrome (HES) is a disorder in which the body has too many eosinophils (a type of white blood cell). Too many eosinophils in HES can cause damage to the heart, nerves, or skin.
- Conditions
- Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder, Hematologic Diseases
- Trial name
- NCT01524536
- Testing
- prednisone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cough, Cough Variant Asthma
MCT and Capsaicin Provocation Challenge in Diagnosis of Chronic Cough
The aim of the study is to assess the prevalence of bronchial hyperresponsiveness (BHR) in non-smoking adults with chronic cough and the prevalence of BHR in patients with upper airway cough syndrome (UACS) and gastroesophageal…
- Conditions
- Cough, Cough Variant Asthma, Upper-Airway Cough Syndrome, GERD
- Trial name
- NCT03363698
- Testing
- Cough variant asthma treatment
- Where
- Poland
- Volunteers
- 55 people
- Sponsor
- Medical University of Warsaw
Asthma, Reactive Airway Disease
Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma
This study seeks to compare the effectiveness of a single dose of oral dexamethasone versus 5 days of oral prednisone in the treatment of mild to moderate asthma exacerbations to prevent relapse with an unscheduled return visit…
- Trial name
- NCT01241006
- Testing
- Dexamethasone, Prednisone
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Alameda County Medical Center
Multiple Myeloma
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
- Trial name
- FIRST (NCT00689936)
- Testing
- Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
- Where
- 288 sites in United States, Australia and 17 more
- Volunteers
- 1,623 people
- Sponsor
- Celgene
Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
This research study is for liver transplant recipients and their respective living donors. The purpose of this study is: 1. To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells…
- Trial name
- ARTEMIS (NCT02474199)
- Testing
- darTregs, Acetaminophen, Diphenhydramine
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Graft Vs Host Disease, Gastrointestinal Graft-Versus-Host Disease
Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD
Patients with gastrointestinal graft-vs.-host disease are randomized to oral beclomethasone dipropionate (BDP) 8 mg/day or identical placebo tablets for 50 days, along with a 10-day induction course of prednisone.
- Trial name
- NCT00233896
- Testing
- Oral beclomethasone dipropionate (drug)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Enteron Pharmaceuticals
Vasculitis, Wegener's Granulomatosis
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
This study will evaluate the safety and effectiveness of a staged approach to therapy for Wegener's granulomatosis and other systemic vasculitides using prednisone plus cyclophosphamide followed by methotrexate.
- Trial name
- NCT00001473
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058422
- Testing
- darbepoetin alfa, filgrastim, rituximab
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells.
- Trial name
- NCT00002744
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 1,970 people
- Sponsor
- Children's Oncology Group
Prostate Cancer
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
Primary objectives: To determine the maximum tolerated doses (MTDs) of daily lenalidomide and docetaxel given every three weeks and prednisone, as combination therapy to subjects with androgen independent prostate cancer To…
- Trial name
- NCT01378091
- Testing
- Lenalidomide, Docetaxel, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Columbia University
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00004179
- Testing
- rituximab, CHOP regimen, cyclophosphamide
- Where
- 261 sites in Australia, Belgium and 16 more
- Volunteers
- 475 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostatic Neoplasms
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).
- Trial name
- NCT02034552
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Bayer
Heart Transplantation
Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation
The purpose of this study is first to improve or save renal function and second to decrease cardiac risk factors by optimising the immunosuppressive regimen by withdrawing steroids and reducing the Cyclosporine A dose.
- Trial name
- NCT00359658
- Testing
- prednisolon, Mycophenolatmofetile, Cyclosporin A
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Hannover Medical School
Prostate Cancer
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
RATIONALE: GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00087165
- Testing
- GTI-2040, docetaxel, prednisone
- Where
- 5 sites in Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
This is a randomized, open-label, multi-center, phase 2 study of RCHOP with or without VELCADE in adult patients with previously untreated non-(Germinal B-Cell-like) GCB Diffuse Large B-cell Lymphoma (DLBCL).
- Trial name
- NCT00931918
- Testing
- Bortezomib, Rituximab, Cyclophosphamide
- Where
- 70 sites in United States
- Volunteers
- 206 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lymphoblastic Lymphoma
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.
- Trial name
- NCT00187122
- Testing
- Vincristine, Radiation Therapy, Daunomycin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Healthy
Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate
This study will investigate the effect of a single dose of PF-04308515 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test.
- Trial name
- NCT01199029
- Testing
- PF-04308515, Prednisone
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Kidney Transplantation
Regimen Optimization Study
Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit…
- Trial name
- NCT02137239
- Testing
- Thymoglobulin, Belatacept, mycophenolate mofetil(MMF)
- Where
- 20 sites in United States, Argentina
- Volunteers
- 58 people
- Sponsor
- Bristol-Myers Squibb
Takayasu's Arteritis, Giant Cell Arteritis
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms.
- Trial name
- NCT00556439
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Classical Hodgkin Lymphoma
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation.
- Trial name
- KEYNOTE-C11 (NCT05008224)
- Testing
- Pembrolizumab, Doxorubicin, Vinblastine
- Where
- 48 sites in United States, Australia and 9 more
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.